Bharat Biotech to launch Hillchol, its oral cholera vaccine, amid a global shortage. With Phase III trials completed and 200M ...

The Wasatch Ultra Growth Fund—Investor Class underperformed the benchmark with a return of -14.81%. Read more here.

The FDA announced yesterday that it will limit access to Covid-19 vaccines to people 65 years of age and older and others who ...

Antimicrobial-resistant (AMR) “superbugs” contribute to more than 4.5 million deaths globally per year and threaten to make ...

Sheila Mikhail sold her biotech company in a $4 billion deal a few years ago. Now, after battling cancer, she's on a mission ...

Learn more about whether Alvotech or Arrowhead Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Leveraging Northway Biotech’s 20+ years of CDMO expertise, Kaida BioPharma is advancing KAD101, a targeted therapy for ...

Known to develop the next generation of vaccines and medicines, with a focus on cell and gene therapies, the company started ...

BioSpace examines the busiest corporate venture capital arms in the pharmaceutical industry. Novo Holdings, which made ...

Regeneron acquires bankrupt 23andMe for $256M, taking over its DNA database and services while pledging to uphold privacy ...

In March, 23andMe said that it was looking to sell “substantially all of its assets” through a court-approved reorganization plan.

Biotechnology leader Regeneron Pharmaceuticals is acquiring genetic testing firm 23andMe for $256 million following its bankruptcy filing. The deal excludes 23andMe’s telehealth subsidiary, Lemonaid ...